COVID-19：阿斯利康向日本提供电晕疫苗：第一三共，明治制衣制药
新型冠状病毒肺炎（COVID-19）：新冠肺炎（COVID-19）：COVID-19：
英国制药巨头：阿斯利康
阿斯利康正在与英国牛津大学合作开发一种新的冠状病毒疫苗。
6月26日，它宣布已同意与日本政府进行讨论，向日本供应新的冠状病毒疫苗。
与第一三共社和明治控股（HD）集团公司合作，为日本建立生产系统。
供应日本：
阿斯利康和其他公司正在进行新的电晕疫苗的临床试验。
为了向日本供应，阿斯利康将提供疫苗的储备溶液。
第一三共集团：
第一三共集团/第一三共生物技术公司（Sa玉县北本市）和明治HD / KM Biologics（熊本市）将参与其中。
明治高清：
它还将利用明治高清的子公司明治精化制药（中部东京）的疫苗分配和供应计划。
日本经济新闻
https://r.nikkei.com/article/DGXMZO60835900W0A620C2MM8000?s=4
新科罗纳：内阁官房长官“协议是事实”
https://r.nikkei.com/article/DGXMZO60839710W0A620C2000000?n_cid=DSREA001&s=4
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful
AstraZeneca
has picked up manufacturing partners at a rapid clip with a goal to produce 2 billion doses per year of the University of Oxford’s COVID-19 vaccine candidate.
And it may be close to adding to that partner list: The British drugmaker and Daiichi Sankyo are in talks to knock together a supply deal for Japan.
AstraZeneca and Daiichi Sankyo
are chipping away at a Japanese supply deal for Oxford’s adenovirus-based COVID-19 vaccine, AZD1222, that would include fill-finish and storage duties, Daiichi said Friday.
The supply talks
come after AstraZeneca and the Japanese government agreed to sit down at the negotiating table to discuss a possible deal, Daiichi said.
Daiichi Sankyo Biotech,
a subsidiary of the Japanese drugmaker,
plans to receive Oxford’s undiluted vaccine, which it will finish at its own facilities.
FiercePharma